Related Experiment Video

Updated: Jan 28, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.8K

Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy

Dorin Sumanaru1, Loic Josseran2,3, Aben Essid1

  • 1Pediatric Intensive Care Unit, Hôpital Raymond-Poincaré, APHP, 92380, Garches, France.

Pediatric Cardiology
|February 24, 2019
PubMed

Insights

Advances in care prolong Duchenne muscular dystrophy survival, increasing cardiomyopathy risk. Levosimendan effectively treated severe heart failure in a 26-year-old patient with this condition.

Area of Science:

  • Cardiology
  • Genetics
  • Neurology

Background:

  • Duchenne muscular dystrophy (DMD) survival has improved due to clinical advancements.
  • Cardiomyopathy is a common complication in DMD patients, particularly in their third decade.
  • Increased survival rates have led to a higher incidence of DMD-associated cardiomyopathy.

Observation:

  • A 26-year-old male patient with DMD presented with severe acute heart failure.
  • Pneumonia was identified as the trigger for the patient's acute heart failure.
  • The patient's cardiac function was monitored during treatment.

Findings:

  • Levosimendan administration resulted in improved heart function for the patient.
  • The study highlights the efficacy of Levosimendan in managing acute heart failure in DMD patients.
  • Successful treatment demonstrates a potential therapeutic option for DMD-associated cardiac complications.

Implications:

  • Levosimendan may be a valuable therapeutic option for managing acute heart failure in Duchenne muscular dystrophy patients.
  • Further research is warranted to explore the long-term benefits and safety of Levosimendan in this population.
  • Improved management of cardiac complications can enhance the quality of life and survival for individuals with DMD.

Keywords:
Acute heart failureDuchenne muscular dystrophyLevosimendan

More Related Videos

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.2K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
977
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
493
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872